terazosin
Brand: Hytrin
Beers Criteria Prototype: doxazosin
Drug Class: alpha-1 blocker
Drug Family: antihypertensive
Subclass: quinazoline alpha-1 antagonist
Organ Systems: cardiovascular
Mechanism of Action
Selective alpha-1 antagonist; intermediate half-life; dual indication for hypertension and BPH.
alpha-1 adrenergic receptor
Indications
- hypertension
- BPH
Contraindications
- PDE-5 inhibitor use
Adverse Effects
Common
- dizziness
- orthostatic hypotension
- nasal congestion
- fatigue
Serious
- syncope
- IFIS
Pharmacokinetics (ADME)
| Absorption | 90% oral bioavailability |
| Distribution | high protein binding |
| Metabolism | hepatic |
| Excretion | fecal 60%, renal 40% |
| Half-life | 12 hours |
| Onset | 15 min |
| Peak | 1-2 hours |
| Duration | 24 hours |
| Protein Binding | 90-94% |
| Vd | 25 L |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| PDE-5 inhibitors | severe hypotension | major |
Nursing Considerations
- First dose at bedtime
- Inform ophthalmologist before eye surgery (IFIS)
- Once-daily dosing possible (12h half-life)
Clinical Pearls
- Similar efficacy to doxazosin but shorter half-life; often dosed once-daily at bedtime
- IFIS risk same as all alpha-1 blockers
Safety Profile
Pregnancy avoid
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.